X

Trial Profile

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Roflumilast (Primary)
Indications Chronic obstructive pulmonary disease
Focus Registrational; Therapeutic Use
Acronyms AURA
Sponsors ALTANA Pharma; AstraZeneca

Most Recent Events

11 Sep 2013 Pooled analysis presented at the 23rd Annual Congress of the European Respiratory Society.
07 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
28 Sep 2011 Pooled analysis assessing the rate and duration of exacerbations as well as overall steroid use presented at the 21st Annual Congress of the European Respiratory Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com